China Resources Double-Crane Pharmaceutical (Jinan) Co., Ltd.

Primary Objective: To compare the extent and rate of absorption of the test formulation, 75 mg polyprednisolone zinc orally disintegrating tablets (supplied by China Resources Double Crane Limin Pharmaceuticals (Jinan) Co., Ltd.), and the reference formulation, 75 mg polyprednisolone zinc orally disintegrating tablets (trade name: Promac® D) from Zeria Shinyaku Kogyo Co., Ltd., in healthy Chinese subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objectives: 1) To evaluate the safety of the test formulation and the reference formulation in healthy Chinese subjects under fasting and fed conditions. 2) To evaluate the oral texture of the formulations in healthy Chinese subjects under fasting and fed conditions, and to provide evidence for the oral texture of polyprednisolone zinc orally disintegrating tablets.

Main purpose: To compare the differences in the degree and rate of absorption of aluminum magnesium aspirin tablets (II) (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. and aluminum magnesium aspirin tablets (II) (trade name: BUFFERIN Combination Tab. A81; specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) certified by Lion Corporation in healthy Chinese population under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of BUFFERIN Combination Tab. A81 (Specification: Each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. and BUFFERIN Combination Tab. A81 (Specification: Each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) certified by Lion Corporation in healthy study participants under fasting and postprandial conditions.

Main research purpose: According to the relevant provisions of bioequivalence test, the nifedipine controlled-release tablets (trade name: Bayer AG; specification: 30 mg) certified by Bayer AG were selected as the reference preparation, and the test preparation nifedipine controlled-release tablets (specification: 30 mg) produced and provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. were subjected to fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation nifedipine controlled-release tablets (specification: 30 mg) and the reference preparation nifedipine controlled-release tablets (trade name: Bayer AG; specification: 30 mg) by healthy subjects.